Incidence of Rotavirus and Circulating Genotypes in Northeast Brazil during 7 Years of National Rotavirus Vaccination

Background and Aims Rotavirus causes severe diarrhoea and Brazil introduced the Rotarix G1P[8] vaccine in 2006. We aimed to describe changes in rotavirus incidence and diarrhoea epidemiology before and after vaccine introduction. Methods Design: (i) hospital-based survey of children with diarrhoea (2006–2012); (ii) diarrhea-mortality and hospitalization surveillance (1999–2012). Setting (i) Aracaju and (ii) state and national level. Results 1841 children were enrolled and 231 (12.5%) had rotavirus. Rotavirus was less frequent from January-June than from July-December (9.4% versus 20.9%, p<0.01), but the seasonal variation was less defined after 2009. Very few rotavirus cases (8–3.9%) were detected in 2011, with an increase in 2012 (13–18.5%). In 2006, unvaccinated children were more likely to have rotavirus, but thereafter unvaccinated and vaccinated children had equally low incidence. Older children and those with rotavirus were more likely to have severe diarrhea episodes. The most frequent genotype from 2006 to 2010 was G2P[4]; except in 2009, when most cases were G1P[8]. Very few G2P[4] were detected from 2011 and 50% cases in 2012 were G8P[4]. Diarrhoea-hospitalizations decreased nationally from 89,934 (2003) to 53,705 (2012; 40.3% reduction) and in the state from 1729 to 748 (56.7% reduction). Diarrhoea-deaths decreased nationally from 4368 in 1999 to 697 in 2012 (84% reduction, p<0.001) and in the state from 132 to 18 (86% reduction). These changes were much larger after vaccine introduction. Conclusions The vaccine was associated with substantial reductions in rotavirus incidence and diarrhoea-hospitalizations and deaths. The G2P[4] genotype predominance disappeared over time and may be replaced by other heterotypic genotypes.

[1]  J. Matthijnssens,et al.  Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  J. Muyembe,et al.  Molecular Surveillance of Rotavirus Infection in the Democratic Republic of the Congo August 2009 to June 2012 , 2014, The Pediatric infectious disease journal.

[3]  J. Tate,et al.  Effectiveness and impact of rotavirus vaccines in the United States – 2006–2012 , 2014, Expert review of vaccines.

[4]  G. Armah,et al.  Surveillance for Rotavirus Gastroenteritis in Children Less Than 5 Years of Age in Togo , 2014, The Pediatric infectious disease journal.

[5]  K. Mitiku,et al.  Hospital-based Surveillance for Rotavirus Gastroenteritis in Children Younger Than 5 Years of Age in Ethiopia: 2007–2012 , 2014, The Pediatric infectious disease journal.

[6]  T. Vesikari,et al.  Impact and Effectiveness of RotaTeq® Vaccine Based on 3 Years of Surveillance Following Introduction of a Rotavirus Immunization Program in Finland , 2013, The Pediatric infectious disease journal.

[7]  Martin J. Aryee,et al.  Global Causes of Diarrheal Disease Mortality in Children <5 Years of Age: A Systematic Review , 2013, PloS one.

[8]  A. Ciapponi,et al.  Temporal trends in diarrhea-related hospitalizations and deaths in children under age 5 before and after the introduction of the rotavirus vaccine in four Latin American countries. , 2013, Vaccine.

[9]  J. Tate,et al.  Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Anderson,et al.  Rotavirus vaccination: short-term indirect herd protection, long-term uncertainty , 2013, Expert review of vaccines.

[11]  C. M. Mendes,et al.  Temporal trends of overall mortality and hospital morbidity due to diarrheal disease in Brazilian children younger than 5 years from 2000 to 2010. , 2013, Jornal de pediatria.

[12]  J. Matthijnssens,et al.  Group A rotavirus universal mass vaccination: how and to what extent will selective pressure influence prevalence of rotavirus genotypes? , 2012, Expert review of vaccines.

[13]  A. Dey,et al.  Changes in hospitalisations for acute gastroenteritis in Australia after the national rotavirus vaccination program , 2012, The Medical journal of Australia.

[14]  B. Cheuvart,et al.  Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins. , 2011, Vaccine.

[15]  A. Nurchi,et al.  Epidemiology and prevention of rotavirus infection: an underestimated issue? , 2011, The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians.

[16]  M. Kundi,et al.  Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. , 2011, Vaccine.

[17]  A. Ciapponi,et al.  Burden and typing of rotavirus group A in Latin America and the Caribbean: systematic review and meta‐analysis , 2011, Reviews in medical virology.

[18]  J. Matthijnssens,et al.  Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. , 2010, Vaccine.

[19]  S. Todd,et al.  Rotavirus strain types circulating in Africa: Review of studies published during 1997-2006. , 2010, The Journal of infectious diseases.

[20]  Manish M Patel,et al.  Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. , 2010, The Journal of infectious diseases.

[21]  T. R. Oliveira,et al.  Tendencias de la internación y de la mortalidad infantil por diarrea: Brasil, 1995 a 2005 , 2010 .

[22]  Toyoko Nakagomi,et al.  Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. , 2009, Gastroenterology.

[23]  L. Cuevas,et al.  Effect of rotavirus vaccination on circulating virus strains , 2008, The Lancet.

[24]  L. Cuevas,et al.  Predominance of Rotavirus P[4]G2 in a Vaccinated Population, Brazil , 2007, Emerging infectious diseases.

[25]  Penelope H Dennehy Rotavirus vaccines--an update. , 2007, Vaccine.

[26]  T. Vesikari,et al.  Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.

[27]  J. Heyse,et al.  Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. , 2006, The New England journal of medicine.

[28]  Toyoko Nakagomi,et al.  Incidence and burden of rotavirus gastroenteritis in Japan, as estimated from a prospective sentinel hospital study. , 2005, The Journal of infectious diseases.

[29]  G. Browning,et al.  Rotavirus serotype G3 predominates in horses , 1992, Journal of clinical microbiology.

[30]  Rotavirus vaccines WHO position paper: January 2013 - Recommendations. , 2013, Vaccine.

[31]  M. Latorre,et al.  Trends in hospital admission and infant mortality from diarrhea: Brazil, 1995-2005. , 2010, Revista de saude publica.